We have previously reported that ERβ2 is associated with poor prognosis in ERα-negative BC and with higher risk of late relapse of AΕΤ-treated early-stage ERα-positive BC, while ERβ1 is associated with lower risk of early relapse of AET-treated early-stage ERα-positive BC [29,30]. The gene discussed is ESR1; the disease is breast cancer.